-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

Benzinga·03/12/2026 17:13:04
Listen to the news
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.